Treatment choice in mild to moderate sleep apnoea in the European Sleep Apnea Database
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00083355" target="_blank" >RIV/65269705:_____/25:00083355 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00143827
Result on the web
<a href="https://publications.ersnet.org/content/erjor/11/6/00360-2025" target="_blank" >https://publications.ersnet.org/content/erjor/11/6/00360-2025</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1183/23120541.00360-2025" target="_blank" >10.1183/23120541.00360-2025</a>
Alternative languages
Result language
angličtina
Original language name
Treatment choice in mild to moderate sleep apnoea in the European Sleep Apnea Database
Original language description
INTRODUCTION: In mild to moderate obstructive sleep apnoea (OSA), positive airway pressure (PAP) and mandibular advancement devices (MADs) are recommended treatments according to guidelines. This cross-sectional study aimed to determine the clinical and organisational predictors for treatment recommendations in mild to moderate OSA. METHODS: In the European Sleep Apnea Database, factors predicting the choice of MAD or PAP treatment were determined in patients with newly diagnosed mild to moderate OSA. Accessibility and reimbursement of MADs study sites was obtained via questionnaire. The regression model included anthropometrics, Epworth Sleepiness Scale score, OSA severity, MAD accessibility and reimbursement, and a comorbidity index variable. RESULTS: 6618 (65.5%) patients received PAP and 3491 (34.5%) were recommended MADs. MAD recommendations varied between centres (0% to 76%). Significant factors favouring MADs include mild versus moderate OSA (odds ratio 6.0, 95% CI 5.3-6.8), negligible versus moderate intermittent hypoxia (OR 2.0, 95% CI 1.7-2.4), no versus excess daytime sleepiness (OR 2.6, 95% CI 2.1-3.1), a comorbidity index score of 0 compared to 3 or more (OR 3.8, 95% CI 3.1-4.6) and no insomnia diagnosis versus diagnosed insomnia (OR 2.0, 95% CI 1.7-2.4). MAD accessibility and reimbursement predicted MAD treatment recommendations (OR 2.3, 95% CI 1.8-2.9 and OR 1.5, 95% CI 1.4-1.7, respectively). CONCLUSION: In mild to moderate OSA, MADs are less frequently recommended than PAP, particularly amongst patients with a higher disease burden. MADs were more frequently used when they were more accessible and reimbursed. Thus, MADs are likely an underused treatment in mild to moderate OSA.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ERJ Open Research
ISSN
2312-0541
e-ISSN
2312-0541
Volume of the periodical
11
Issue of the periodical within the volume
6
Country of publishing house
GB - UNITED KINGDOM
Number of pages
14
Pages from-to
00360-2025
UT code for WoS article
001669376900001
EID of the result in the Scopus database
—